Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6088 in Advanced/Metastatic Solid Tumors
NCT07857135Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Feb 2029
01
Overview
Phase 2, randomised, open-label trial of SYS6088 in solid tumor (10 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SYS6088
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07857135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857135.